Plaque

NaturVet unleashes innovative Breed Specific Soft Chew® line for five breed categories

Retrieved on: 
Tuesday, April 16, 2024
Giant, Personality, Temperament, Pet, Health, Heart, Parent, Bad breath, Dog, Allergy, Anxiety, Plaque

TEMECULA, Calif., April 16, 2024 /PRNewswire-PRWeb/ -- NaturVet, the 30-year pioneer and present-day innovator of the pet health and wellness industry, announces the latest innovation in the pet supplement realm: Breed Specific Soft Chews®. This new comprehensive line is made up of five products that provide proactive, personalized support for distinct dog breed categories, including Toy/Small, Bully, Sport/Working, Doodle and Giant.

Key Points: 
  • Developed and manufactured by NaturVet in California, the vet-formulated soft chew line was designed to offer a streamlined and personalized supplement approach for breeds with particular health needs.
  • CLICK TO POST: 🐾 @NaturVet announces the industry's first comprehensive breed specific supplement line for dogs!
  • Our Breed Specific line provides simplified, yet specialized support for breed and size needs that is approachable for all dog parents."
  • To learn more about the new Breed Specific Soft Chew line from NaturVet, please visit https://naturvet.com/ .

TARTAR SHIELD LAUNCHES DIRECT2VET PORTAL FOR EASIER PURCHASING BY VETERINARY PROFESSIONALS

Retrieved on: 
Friday, April 12, 2024
Periodontal disease, Student, Plaque, Dentistry

NOBLESVILLE, Ind., April 11, 2024 /PRNewswire/ -- Tartar Shield Pet Products, Inc. , a leading manufacturer and distributor of pet dental health products, announces the launch of Direct2Vet , an online portal designed to simplify the way veterinary professionals and students purchase pet dental products.

Key Points: 
  • NOBLESVILLE, Ind., April 11, 2024 /PRNewswire/ -- Tartar Shield Pet Products, Inc. , a leading manufacturer and distributor of pet dental health products, announces the launch of Direct2Vet , an online portal designed to simplify the way veterinary professionals and students purchase pet dental products.
  • "Veterinary professionals have countless daily demands," said Lisa Hoover, President of Tartar Shield.
  • "Our Direct2Vet portal offers the most convenient, fast ordering of our popular Tartar Shield products, getting the products to the vet, and then onto the customer sooner than ever.
  • Veterinary professionals must register to use the Direct2Vet portal.

Suburban Propane Supports Anaheim Ducks' Green Night on April 9th with Donation to Anaheim Ducks Foundation

Retrieved on: 
Wednesday, April 10, 2024
Rubber duck race, Honda Center, Natural gas, Anaheim Ducks, Sport, Marketing, Partnership, Electricity, Propane, Carbon, Environmentalism, NHL, Ice, National Hockey League, Plaque, Organization, Duck

ANAHEIM, Calif., April 10, 2024 /PRNewswire/ -- Suburban Propane Partners, L.P., a nationwide distributor of propane, renewable propane, renewable natural gas, fuel oil and related products and services, as well as a marketer of natural gas and electricity and investor in low carbon fuel alternatives, joined forces with the Anaheim Ducks on April 9th to celebrate the team's Green Night game. Suburban Propane President and CEO, Michael Stivala, presented a plaque to Merit Tully, Vice President, Marketing at the Anaheim Ducks, marking both organizations' commitment to a greener-energy future. This partnership also includes a generous donation to the Anaheim Ducks Foundation, demonstrating their shared dedication to sustainability and community support.

Key Points: 
  • This collaboration is backed by Suburban Propane's 'Go Green with Suburban Propane' corporate initiative, highlighting the clean burning attributes of propane and renewable propane.
  • "We are thrilled to mark Earth Month alongside our new partner, the Anaheim Ducks, during their Green Night game," said Nandini Sankara, Spokesperson for Suburban Propane.
  • As an official propane partner of the team, Suburban Propane powers the Anaheim Ducks' Zamboni® Ice Resurfacing Machine, which features the Go Green with Suburban Propane company branding.
  • To learn more about Suburban Propane's "Go Green with Suburban Propane" corporate pillar, please visit https://www.suburbanpropane.com/suburban-propane-experience/go-green/ .

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on: 
Wednesday, April 10, 2024
Tsinghua University, OCTA, Alzheimer's disease, Finance, CE, Patient, Artificial intelligence, Adolescence, World's fair, Medical device regulation, Dementia, CNV, Certification, Hyperthyroidism, HK, Partnership, Policy, MICCAI, Safety, Lighting, Optical coherence tomography angiography, Intelligence, Choroidal neovascularization, Journal, Hospital, Research, Near-sightedness, Amblyopia, AI, Insurance, Strabismus, AMD, Gold medal, Diagnosis, Peking University, Conference, Growth, Biomarker, Plaque, News, Bleeding, Google Images, Rehabilitation, Medical device

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points: 
  • Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
    On March 27, medical artificial intelligence company Airdoc Technology (2251.
  • In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
  • In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
  • In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
Monday, April 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Monday, April 8, 2024
Prior, Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, April 2, 2024
Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc.

Retrieved on: 
Monday, April 1, 2024
Psoriasis, District court, Defendant, News, IPO, Inflammation, Plaque, Complaint, Action Replay, Court, Advertising, Security (finance)

Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .

Key Points: 
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Sunday, March 31, 2024
Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.